Adprotech company
Adprotech is a biopharmaceutical company, develops pharmaceutical products for the treatment of organ transplant rejection, rheumatoid arthritis, bacterial infection, and stroke diseases. It develops and applies Prodaptin, a platform technology that increases the efficacy of therapeutics by targeting specific cells or tissues.
Technology:
Regenerative Medicine
Industry:
Biotechnology, Health Care, Science and Engineering
Headquarters:
Saffron Walden, Essex, United Kingdom
Funding Status:
M&A
Investors Number:
2
Total Funding:
$27.2M
Last Funding Type:
Series B
Register and Claim Ownership